Possible Therapeutic Role of Cholinergic Agonists on Covid-19 Related Inflammatory Response

Abstract

Severe acute respiratory syndrome-corona virus-2 (SARS-CoV-2) or coronavirus infectious disease (COVID-19) outbreak is continued to spread all over the world recently with the high mortality and morbidity rates. It is also known well COVID-19 is leading causes of acute lung injury and acute respiratory distress syndrome (ARDS), sepsis and multiorgan failure. Current treatment of COVID-19, includes different strategies targeting preventing viral replication or treating secondary infections and decreasing exaggerated immune response. Although antiviral, antimicrobial, immunomodulatory agents including anti-cytokines and glucocorticoids have been currently applied, there is lack of a specific treatment for COVID-19. In this review, possible therapeutic roles of cholinomimetic drugs in the control of COVID-19 related inflammation is discussed.